#### **ICD-11** : FA60.0
- #### **Key Features**
- **Onset**: Rapid (hours to days), systemic symptoms (fever, chills).
- **Pathophysiology**:
	- **Hematogenous spread**: Bacteria seed metaphysis in children (due to sluggish blood flow in tortuous metaphyseal capillaries).
	- **Direct inoculation**: Trauma/surgery (adults).
	- **Common pathogens**: #ortho-prof-card
		- Children: *S. aureus* (90%), *Kingella kingae* (under 5 yrs), *Group B Strep* (neonates).
		- Sickle cell: *Salmonella*.
	- **Metaphyseal Predilection**:
		- Vascular loops trap bacteria → abscess formation.
	- **Growth Plate (Physis) Injury**:
		- **Infants**: Transphyseal vessels → direct spread → growth arrest.
		- **Older children**: Physis acts as barrier → deformity rare unless severe.
- #### **Clinical Presentation**
- **Children**:
	- Refusal to bear weight, metaphyseal tenderness (e.g., distal femur, proximal tibia).
	- **Growth plate risk**: Infection can cross physis in infants (<18 months) → growth arrest/deformity (e.g., limb shortening, angular deformity).
- **Adults**: Vertebral pain (thoracolumbar), may mimic discitis.
- #### **Diagnosis**
- **Labs**: ↑ESR/CRP (sensitive but nonspecific), blood cultures (+ in 50% of children).
- **Imaging**:
	- **X-ray**: Normal first 7–10 days; later shows periosteal elevation/lytic lesions.
	- **MRI**: Gold standard (bone marrow edema, subperiosteal abscess).
	- **Bone scan**: Useful if multifocal (e.g., neonates).
- #### **Management Protocol** #ortho-prof-card
- **Empirical Antibiotics** (start after blood/tissue cultures):
	- **Children**:
		- **MSSA**: IV cefazolin/nafcillin (50–100 mg/kg/day).
		- **MRSA/neonates**: Vancomycin + cefotaxime (covers *Group B Strep*).
	- **Adults**: Vancomycin + piperacillin-tazobactam (broad-spectrum).
- **Surgical Drainage** if:
	- Abscess (subperiosteal/soft tissue).
	- No clinical improvement in 48h.
- **Duration**:
	- IV antibiotics for 2–4 weeks → oral (total 4–6 weeks).
	- Transition to oral when: Afebrile, CRP ↓ >50%, pain improved.
- #### **Complications** #ortho-prof-card
- **Septic arthritis** (hip/shoulder if metaphysis intra-articular).
- **Chronic osteomyelitis** (5–30% if delayed treatment).
- **Growth arrest** (asymmetric physeal damage → limb deformity).
- **Pathologic fracture** (lytic weakening of cortex).
-
- **DDx**:
	- **Transient synovitis**: No fever, normal CRP.
	- **Septic arthritis**: Joint effusion, painful ROM.
-
-
alias::
ICD-11_Code::
tags:: #Disease, #[[Inflammatory Disease]], #Orthopedics

- ## Etiology
  background-color:: blue
	- ### Causative Agents #ortho-prof-card
	- ### Risk Factors
- ## Epidemiology
  background-color:: blue
	- ### Incidence
	- ### Prevalence
		- ### Demographics
	- ### Geographic Distribution
- ## Pathophysiology
  background-color:: blue
	- ### Mechanism of Disease
	- ### Affected Systems/Organs
- ## Clinical Features
  background-color:: blue
	- ### Clinical Presentation
		- #### Symptoms
		- #### Signs
	- ### Stages or Classification
	- ### Diagnostic Criteria
- ## Diagnosis
  background-color:: blue
	- ### Clinical Diagnosis
		- #### Classical Presentation
		- #### Probable Diagnosis
	- ### Laboratory Tests
	- ### Imaging Studies
	- ### Differential Diagnosis
	- ### Confirmation of Diagnosis
- ## Management and Treatment
  background-color:: blue
	- ### Management Protocol #ortho-prof-card
	- ### Medical Treatment
	- ### Surgical Options
	- ### Lifestyle and Dietary Recommendations
	- ### Follow-up
- ## Prognosis
  background-color:: blue
	- ### Expected Course
		- ### Complications #ortho-prof-card
		- #### With Treatment
		- #### Without Treatment
			- ##### Possible Complications
			- ##### Long-Term Effects
	- ### Survival Rates
		- #### With Treatment
		- #### Without Treatment
	- ### Quality of Life Considerations
- ## Prevention
  background-color:: blue
	- ### Health Education
	- ### Community Approach
	- ### Screening Programs
	- ### Lifestyle Modifications
- ## Patient Education and Support
  background-color:: blue
	- ### Educational Resources
	- ### Support Groups
	- ### Counseling Options
- ## Recent Research and Developments
  background-color:: blue
	- ### Ongoing Clinical Trials
	- ### Recent Advances
- ## Key Literature
  background-color:: blue
- ## Guidelines and Protocols
  background-color:: blue